ArticleCureus2025
Treatment of Methotrexate-Associated Lymphoproliferative Disorder With Biological Therapies.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphoproliferative disorders may arise as a complication of immunosuppressant medications, such as methotrexate. This case report describes a patient who developed a rare subtype of methotrexate-associated lymphoproliferative disorder. His disease initially responded well to the withdrawal of methotrexate. However, several months after diagnosis, surveillance testing revealed progressive lymphadenopathy. Owing to his multiple comorbidities and resultant poor baseline functional status, he was not a candidate for cytotoxic chemotherapy. Based on key histopathological characteristics of his rare disorder, his care team devised an alternative therapy, consisting of rituximab and brentuximab, a unique protocol that is not well-described in the lymphoma literature. The patient achieved a brief but complete remission from this therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.